Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Blood (2024) 144 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2024-198499

Published: 2024

Journal Articles

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Blood (2024) 144 (Supplement 1): 922.

https://doi.org/10.1182/blood-2024-201356

Published: 2024

Journal Articles

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

Blood blood.2024025945.

https://doi.org/10.1182/blood.2024025945

Published: 2024

Includes: Supplemental data

Journal Articles

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Blood (2023) 142 (Supplement 1): 219.

https://doi.org/10.1182/blood-2023-181857

Published: 2023

Journal Articles

Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant

David Tong Chen, Olga Goloubeva, Hanan Alkhaldi, Aaron P. Rapoport, Saurabh Dahiya, Nancy M. Hardy, Djordje Atanackovic, Mehmet Hakan Kocoglu, Forat Lutfi, Jean A. Yared

Blood (2022) 140 (Supplement 1): 9526–9527.

https://doi.org/10.1182/blood-2022-158281

Published: 2022

Journal Articles

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Blood (2022) 140 (Supplement 1): 1856–1858.

https://doi.org/10.1182/blood-2022-164884

Published: 2022

Journal Articles

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 10427–10429.

https://doi.org/10.1182/blood-2022-163464

Published: 2022

Journal Articles

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, M. Hakan Kocoglu, Omar Nadeem, Myo Htut, Tara Gregory, Larry D. Anderson, Jr., Luciano J. Costa, Tonia J. Buchholz, Safiyyah Ziyad, Meng Li, Yanping Chen, Allison J. Kaeding, Michael R. Burgess, Kristen Hege, Jesus Berdeja

Blood (2022) 140 (Supplement 1): 883–885.

https://doi.org/10.1182/blood-2022-162395

Published: 2022

Journal Articles

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Blood (2022) 140 (Supplement 1): 4642–4645.

https://doi.org/10.1182/blood-2022-164828

Published: 2022

Journal Articles

Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Blood (2022) 140 (Supplement 1): 10377–10379.

https://doi.org/10.1182/blood-2022-166058

Published: 2022

Journal Articles

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Blood (2022) 140 (Supplement 1): 623–625.

https://doi.org/10.1182/blood-2022-158478

Published: 2022

Journal Articles

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Saurabh Dahiya, Tim Luetkens, Stephanie Avila, Saurabh Dahiya, Philip Margiotta, Kim Hankey, Patricia Lesho, Sherri Bauman, Nancy Smith, Kathleen Ruehle, Seung-Tae Lee, Jennie Y. Law, John Baddley, Mehmet Hakan Kocoglu, Jean A. Yared, Nancy M. Hardy, Aaron P. Rapoport, Djordje Atanackovic

Blood (2021) 138 (Supplement 1): 1738.

https://doi.org/10.1182/blood-2021-153949

Published: 2021

Journal Articles

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Blood (2021) 138 (Supplement 1): 3876.

https://doi.org/10.1182/blood-2021-154225

Published: 2021

Journal Articles

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Blood (2021) 138 (Supplement 1): 3858.

https://doi.org/10.1182/blood-2021-151672

Published: 2021

Journal Articles

Impact of Induction Treatment on Stem Cell Collection: A COVID Related Study

Brad Rybinski, Ashraf Z. Badros, Aaron P. Rapoport, Mehmet Hakan Kocoglu

Blood (2021) 138 (Supplement 1): 4848.

https://doi.org/10.1182/blood-2021-149812

Published: 2021

Journal Articles

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Dong Won Kim, MD, Forat Lutfi, MD, Facundo Zafforoni, BS, Moaath Mustafa Ali, MD MPH, Ali Bukhari, MD, David Gottlieb, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Nancy M. Hardy, MD, Jean A. Yared, MD, Aaron P. Rapoport, MD, Jennie Y. Law, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141992

Published: 2020

Journal Articles

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Forat Lutfi, MD, Ankit Kansagra, MD, Moaath Mustafa Ali, MD, Ali Bukhari, MD, Jonathan Siglin, BS, Jingsheng Yan, PhD, Santanu Samanta, MD, Noa G. Holtzman, MD, David Gottlieb, MD, Dong Won Kim, MD, Seung-Tae Lee, MD PhD, Mehmet Hakan Kocoglu, MD, Jean A. Yared, MD, Nancy M. Hardy, MD, Jason Molitoris, MD, Pranshu Mohindra, MD, Aaron P. Rapoport, MD, Saurabh Dahiya, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-141231

Published: 2020

Journal Articles

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin L. Costello, MD, Adam D. Cohen, MD, Krina K. Patel, MD, Syed S Ali, MD, Jesus G. Berdeja, MD, Nina Shah, MD, Siddhartha Ganguly, MD, Mehmet Hakan Kocoglu, MD, Mehrdad Abedi, MD, Eric M. Ostertag, MD PhD, Chris E Martin, PhD, Majid Ghoddussi, PhD, Devon J Shedlock, PhD, Joanne McCaigue, M.S., Hamid Namini, PhD, Sreeni Yalamanchili, Matthew A. Spear, MD, Tara K. Gregory, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142695

Published: 2020

Journal Articles

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

Ali Bukhari, MD, Vivek Kesari, MD, Reza Sirous, MD, Noa G. Holtzman, MD, Seung Tae Lee, MD PhD, Natalie Gahres, RN, Elizabeth Hutnick, RN, Kathleen Ruehle, RN, Mehmet Hakan Kocoglu, MD, Ashraf Z. Badros, Jean A. Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, Babak Saboury, MD MPH, Saurabh Dahiya, MD

Blood (2019) 134 (Supplement_1): 4454.

https://doi.org/10.1182/blood-2019-125794

Published: 2019

Journal Articles

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Noa G. Holtzman, MD, Soren M. Bentzen, PhD DMSc, Vivek Kesari, MD, Ali Bukhari, MD, Firas El Chaer, MD, Elizabeth Hutnick, RN, Kathleen Ruehle, RN, Natalie Gahres, RN, Neil Porter, MD, Carl Shanholtz, MD, Mehmet Hakan Kocoglu, MD, Ashraf Z. Badros, Babak Saboury, MD MPH, Jean A. Yared, MD, Nancy M. Hardy, MD, Aaron P. Rapoport, Saurabh Dahiya, MD

Blood (2019) 134 (Supplement_1): 3239.

https://doi.org/10.1182/blood-2019-125400

Published: 2019

NARROW

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)

Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma

BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 Study

Clinical Outcomes of CD19 CAR-T-Cell Therapy with Axi-Cel in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) with and without Prior Autologous Stem Cell Transplant

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Clinical Activity of BMS-986393 (CC-95266), a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy

Impaired mRNA Based COVID-19 Vaccine Response in Patients with B-Cell Malignancies after CD19 Directed CAR-T Cell Therapy

Imaging Biomarkers to Predict Outcomes in Patients with Large B-Cell Lymphoma with a Day 28 Partial Response By PET/CT Imaging Following CAR-T Therapy

Clinical Trials of BCMA-Targeted CAR-T Cells Utilizing a Novel Non-Viral Transposon System

Impact of Induction Treatment on Stem Cell Collection: A COVID Related Study

Low Utility of the H-Score and HLH-2004 Criteria to Identify Patients with Secondary Hemophagocytic Lymphohistiocytosis after CAR-T Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

The Impact of Bridging Therapy Prior to CAR-T Cell Therapy on Clinical Outcomes of Patients with Relapsed Refractory Large B-Cell Lymphoma

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier

Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy (CAR-T) for Large B-Cell Lymphoma: Predictive Biomarkers and Clinical Outcomes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only